New BTK-Degrader cocktail takes on Hard-to-Treat blood cancers

NCT ID NCT06634589

Recruiting now Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 37 times

Summary

This study is testing a new oral drug called BGB-16673, which breaks down a protein that helps cancer cells grow, in combination with other cancer drugs. It is for people with B-cell cancers (like certain lymphomas) that have come back or stopped responding to treatment. The trial will enroll about 80 participants and will first check safety and the right dose, then look at whether the tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi
RECRUITING

Bologna, 40138, Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, 20162, Italy
Centroricerche Cliniche Di Verona Srl
RECRUITING

Verona, 37134, Italy
Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Ensino E Terapia de Inovacao Clinica Amo Etica
RECRUITING

Salvador, 41950-640, Brazil
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111-2434, United States
Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, 350001, China
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
RECRUITING

São José do Rio Preto, 15090-000, Brazil
Hospital Sirio Libanes Brasilia
RECRUITING

Brasília, 70200-730, Brazil
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112-5550, United States
Icahn School of Medicine At Mount Sinai
RECRUITING

New York, New York, 10029-6504, United States
Istituto Clinico Humanitas
RECRUITING

Rozzano, 20089, Italy
Istituto Nazionale Tumori Fondazione G Pascale
RECRUITING

Naples, 80131, Italy
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, WA 6009, Australia
Mater Cancer Care Centre
RECRUITING

South Brisbane, Queensland, QLD 4101, Australia
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224-1865, United States
Mayo Clinic Phoenix
RECRUITING

Phoenix, Arizona, 85054-4502, United States
Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905-0001, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226-1222, United States
Medizinische Universitaetsklinik
RECRUITING

Tübingen, 72076, Germany
Memorial Sloan Kettering Cancer Center Mskcc
RECRUITING

New York, New York, 10065-6800, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612-9496, United States
Monash Health
RECRUITING

Clayton, Victoria, VIC 3168, Australia
Narodowy Instytut Onkologii Im Marii Sklodowskiej Curie Hematology Unit
RECRUITING

Warsaw, 02-781, Poland
North Shore Hospital
RECRUITING

Auckland, 0622, New Zealand
Peter Maccallum Cancer Centre
RECRUITING

Melbourne, Victoria, VIC 3000, Australia
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
RECRUITING

São Paulo, 05652-900, Brazil
St George Hospital
RECRUITING

Kogarah, New South Wales, NSW 2217, Australia
Summit Medical Group
RECRUITING

Florham Park, New Jersey, 07932-1049, United States
Sun Yat Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Szpital Kliniczny Mswia Z Warmisko Mazurskim Centrum Onkologii
RECRUITING

Olsztyn, 10-228, Poland
Szpital Wojewodzki W Opolu Sp Z Oo Oddzia Hematologii I Onkologii Hematologicznej
RECRUITING

Opole, 45-061, Poland
The Alfred Hospital
RECRUITING

Melbourne, Victoria, VIC 3004, Australia
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
RECRUITING

Hangzhou, Zhejiang, 310002, China
The University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205-2003, United States
The University of Texas Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
Universitaetsklinikum Ulm
RECRUITING

Ulm, 89081, Germany
Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
RECRUITING

Dresden, 01307, Germany
Universitatsklinikum Jena Klinik Fur Innere Medizin Ii
RECRUITING

Jena, 07747, Germany
Universitatsklinikum Schleswig Holstein Campus Kiel
RECRUITING

Kiel, 24105, Germany
University of Rochester
RECRUITING

Rochester, New York, 14642-0001, United States
University of Southern California Norris Comprehensive
RECRUITING

Los Angeles, California, 90033, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792-0001, United States
Uniwersytecki Szpital Kliniczny Nr 1 W Lublinie
RECRUITING

Lublin, 20-081, Poland
Uniwersyteckie Centrum Kliniczne
RECRUITING

Gdansk, 80-214, Poland
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110-1010, United States
Weill Cornell Medical College Newyork Presbyterian Hospital
RECRUITING

New York, New York, 10065-4870, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BGB-16673 (a BTK-degrader) taken orally, combined with other drugs such as sonrotoclax, zanubrutinib, mosunetuzumab, glofitamab, or obinutuzumab

What this could lead to

If successful, this could point toward a new treatment option for people with B-cell cancers that have stopped responding to standard therapies.

What could go wrong

This is an early (phase 1b/2) and small (80 participants) trial focused on safety and dosing, so it is too soon to know if the combinations will work. Side effects from the drug combinations are possible and will be closely monitored.

Conditions

The condition(s) this trial relates to.

B-cell neoplasm neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LYMPHOMA B-CELL LYMPHOMA B-CELL MALIGNANCY B-CELL MALIGNANCY REFRACTORY CANCER RELAPSED CANCER RELAPSED CANCER